Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial results. Corporate Highlights Completed GMP manufacture of Gemini clinical drug supply Received net proceeds of $3.8 million from the exercise of warrants in August 2024 Announced Gemini induces dose dependent significant increases in IL-10 in healthy volunteers "The Revelation team continues to make significan
11/8/24 4:15:00 PM ET
$REVB
Biotechnology: Pharmaceutical Preparations
Health Care
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and six months ended June 30, 2024 financial results. Corporate Highlights Completed dosing of its first in human phase 1 clinical study of Gemini Announced positive phase 1 clinical data of Gemini met the primary safety endpoint and showed statistically significant biomarker activity "The Revelation team has worked hard in the first half of 2024 to continue
8/9/24 4:15:00 PM ET
$REVB
Biotechnology: Pharmaceutical Preparations
Health Care
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three months ended March 31, 2024 financial results. Results of Operations As of March 31, 2024, Revelation had $14.6 million in cash and cash equivalents, compared to $12.0 million as of December 31, 2023. The increase in cash and cash equivalents was primarily due to net cash received from financing activities, offset primarily by cash used for operating activities. Based on current operating plans and projections, Revelation believes that its curren
5/10/24 4:52:00 PM ET
$REVB
Biotechnology: Pharmaceutical Preparations
Health Care

$REVB
Leadership Updates

Live Leadership Updates

Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced the appointment of Lakhmir Chawla M.D. to the Company's Board of Directors (Board). "We are excited to welcome Dr. Chawla as an independent director to our Board," said James Rolke, Chief Executive Officer of Revelation. "Dr. Chawla brings decades of expertise and leadership in key areas such as nephrology, critical care medicine, drug development and strategic implementation. I am confident that he will provide valuable perspectives as we continue to execute our str
10/2/23 9:00:00 AM ET
$REVB
Biotechnology: Pharmaceutical Preparations
Health Care
Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal
Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced that the Company has adjourned its 2023 Annual Meeting of Stockholders (the "Annual Meeting") originally scheduled to be held on June 9, 2023, to July 7, 2023, at 1:00 p.m., Eastern Time, or at such other time or such other date to which the meeting may be adjourned. On June 9, 2023, the Company called to order its Annual Meeting. At the Annual Meeting, there were not present in person or by proxy at least a majority of the Company's common stock outstanding as of th
6/12/23 4:15:00 PM ET
$REVB
Biotechnology: Pharmaceutical Preparations
Health Care
Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board
Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, today announced it has appointed Julia Bohannon, Ph.D. and Antonio Hernandez, M.D. to its scientific advisory board. Dr. Hernandez and Dr. Bohannon are inventors of the phosphorylated hexaacyl disaccharide (PHAD) based technology licensed from Vanderbilt University, previously announced on October 6, 2022. Julia Bohannon, Ph.D. is an Associate Professor in the Department of Anesthesiology and the Department of Pathology, Microbiology and Immunology at Vanderbilt University Medical Ce
3/13/23 9:00:00 AM ET
$REVB
Biotechnology: Pharmaceutical Preparations
Health Care

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced it has successfully completed the GMP manufacture of Gemini drug product to support anticipated clinical studies in the United States. GMP compliant manufacturing of Gemini is a pivotal requirement for an Investigational New Drug (IND) application with FDA. The Company intends to utilize the current supply of Gemini for the upcoming Phase 1b clinical trial in chronic kidney disease (CKD) patients as well as future Phase 2 studies. "We are pleased to have achiev
11/12/24 6:00:00 AM ET
$REVB
Biotechnology: Pharmaceutical Preparations
Health Care
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial results. Corporate Highlights Completed GMP manufacture of Gemini clinical drug supply Received net proceeds of $3.8 million from the exercise of warrants in August 2024 Announced Gemini induces dose dependent significant increases in IL-10 in healthy volunteers "The Revelation team continues to make significan
11/8/24 4:15:00 PM ET
$REVB
Biotechnology: Pharmaceutical Preparations
Health Care
Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced statistically significant, dose dependent increases of interleukin-10 (IL-10) in response to Gemini treatment, using a high sensitivity analysis. This additional positive data follows the previously reported positive topline data from the Phase 1 clinical study of Gemini released on June 24, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240924064564/en/Figure 1. Upregulation of IL-10 at 2 Ho
9/24/24 6:00:00 AM ET
$REVB
Biotechnology: Pharmaceutical Preparations
Health Care

Revelation Biosciences Announces Phase 1 Results For Gemini; Demonstrates Safety, Tolerability, And Dose-Dependent Biomarker Changes; Enables Further Development Across Multiple Indications

Chat with this insight

Recent Analyst Ratings for
$REVB

$REVB
Financials

Live finance-specific insights

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024

$REVB
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Roth Capital initiated coverage on Revelation Biosciences with a new price target

$REVB
Market Insights

Live Market Insights

Revelation Biosciences Files $50M Mixed-Securities Shelf

Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $12.40 Price Valuation

Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?

$REVB
SEC Filings

Revelation Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Revelation Biosciences Inc.

Revelation Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

$REVB
Leadership Updates

Live Leadership Updates

Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors

Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal

Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board

$REVB
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Revelation Biosciences Inc. (Amendment)

SEC Form SC 13G filed by Revelation Biosciences Inc.

SEC Form SC 13G filed by Revelation Biosciences Inc.

$REVB
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Tidmarsh George F sold $14,438 worth of shares (27,771 units at $0.52), closing all direct ownership in the company (SEC Form 4)

Tidmarsh George F sold $1,199 worth of shares (1,845 units at $0.65), decreasing direct ownership by 6% to 27,771 units (SEC Form 4)

Tidmarsh George F sold $7,243 worth of shares (10,957 units at $0.66) (SEC Form 4)

$REVB
Press Releases

Fastest customizable press release news feed in the world

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10

Revelation Biosciences Announces Phase 1 Results For Gemini; Demonstrates Safety, Tolerability, And Dose-Dependent Biomarker Changes; Enables Further Development Across Multiple Indications

Chat with this insight

Recent Analyst Ratings for $REVB

$REVB Financials

Live finance-specific insights

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024

$REVB Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Roth Capital initiated coverage on Revelation Biosciences with a new price target

$REVB Market Insights

Live Market Insights

Revelation Biosciences Files $50M Mixed-Securities Shelf

Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $12.40 Price Valuation

Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?

$REVB SEC Filings

Revelation Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Revelation Biosciences Inc.

Revelation Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

$REVB Leadership Updates

Live Leadership Updates

Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors

Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal

Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board

$REVB Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Revelation Biosciences Inc. (Amendment)

SEC Form SC 13G filed by Revelation Biosciences Inc.

SEC Form SC 13G filed by Revelation Biosciences Inc.

$REVB Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Tidmarsh George F sold $14,438 worth of shares (27,771 units at $0.52), closing all direct ownership in the company (SEC Form 4)

Tidmarsh George F sold $1,199 worth of shares (1,845 units at $0.65), decreasing direct ownership by 6% to 27,771 units (SEC Form 4)

Tidmarsh George F sold $7,243 worth of shares (10,957 units at $0.66) (SEC Form 4)

$REVB Press Releases

Fastest customizable press release news feed in the world

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10

Recent Analyst Ratings for
$REVB

$REVB
Financials

$REVB
Analyst Ratings

$REVB
Market Insights

$REVB
SEC Filings

$REVB
Leadership Updates

$REVB
Large Ownership Changes

$REVB
Insider Trading

$REVB
Press Releases